At the trial’s pre-specified interim analysis, giredestrant achieved a hazard ratio of 0.70, marking a statistically significant improvement in invasive disease-free survival
The study met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in invasive disease-free survival
EBITDA was Rs. 2,359.6 crore in the quarter ended September 30, 2025
Net profit for the half-year rose to Rs. 410 crore from Rs. 351 crore
Positive volume growth was observed in key therapies such as respiratory (13.2% yoy), anti-neoplastics (12.1% yoy) and cardiac (4.8% yoy) during September 2025
Alkem’s domestic business grew 9.7 per cent versus the Indian pharmaceutical market growth of 8.5 per cent
Annual EBITDA margin expands by 170 basis points
For the full year FY25, net profit soared 12x to Rs 345 crore
Approval brings AstraZeneca and Daiichi Sankyo’s Enhertu earlier in the treatment of HR-positive, HER2-low breast cancer and broadens the eligible patient population to those with HER2-ultralow disease
Q3 FY25 revenue up 24% to Rs 3,230 crore
Subscribe To Our Newsletter & Stay Updated
